|
시장보고서
상품코드
1386214
백혈병 치료제 시장 : 동향, 예측 및 경쟁 분석(-2030년)Leukemia Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030 |
||||||
Lucintel
백혈병 치료제의 동향과 전망
세계 백혈병 치료제 시장 규모는 2024-2030년 연평균 8.4% 성장하여 2030년까지 약 214억 6,000만 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 백혈병 발병률 증가, 백혈병의 보다 효과적인 치료에 대한 수요 증가, 의료 산업의 연구 개발 비용 증가입니다. 세계 백혈병 치료제 시장의 미래는 병원 약국, 약국 및 소매 약국, 온라인 제공업체 시장에서 사업 기회가 있어 유망한 것으로 보입니다.
백혈병 치료제 시장 인사이트
Lucintel은 만성 림프성 백혈병에 대한 제품 승인 증가와 만성 림프성 백혈병에 대한 백혈병 치료제의 존재로 인해 예측 기간 동안 만성 림프성 백혈병이 가장 큰 부문로 남을 것으로 예상하고 있습니다.
이 시장에서 병원 약국은 백혈병과 그 치료 옵션에 대한 대중의 인식이 높아지고 병원에서 치료를 받으려는 사람들이 증가함에 따라 가장 큰 부문이 될 것으로 보입니다.
북미는 백혈병 치료제를 위한 재생의료 분야의 연구 증가와 개인 맞춤형 의료에 대한 인식이 높아짐에 따라 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.
시장 규모 및 추정치: 백혈병 치료제 시장 규모를 금액(10억 달러)으로 추정
동향 및 예측 분석 : 각 부문별, 지역별 시장 동향(2018-2023년) 및 예측(2024-2030년)
부문별 분석 : 백혈병 치료제 시장 규모를 유형별, 약품별, 유통채널별, 지역별 금액(10억 달러)으로 추정
지역별 분석 : 백혈병 치료제 시장 북미, 유럽, 아시아태평양 및 기타 지역 분석
전략적 분석 : 백혈병 치료제 시장 유형, 약품, 유통 채널, 지역별 성장 기회 분석
전략적 분석 : 백혈병 치료제 시장의 M&A, 신제품 개발, 경쟁 구도 등
Porter's Five Forces 모델을 기반으로 한 산업 경쟁 강도 분석
이 보고서는 다음과 같은 11가지 주요 질문에 대한 답변을 담고 있습니다.
- Q.1. 시장 부문 중 가장 유망하고 성장성이 높은 기회는 무엇인가?
- Q.2. 어떤 부문이 더 빠른 속도로 성장할 것이며, 그 이유는 무엇인가?
- Q.3. 향후 성장이 가속화될 것으로 예상되는 지역과 그 이유는?
- Q.4. 시장 역학에 영향을 미치는 주요 요인은? 시장의 주요 과제와 비즈니스 리스크는 무엇인가?
- Q.5. 이 시장에서의 비즈니스 리스크와 경쟁 위협은 무엇인가?
- Q.6. 이 시장의 새로운 트렌드와 그 이유는?
- Q.7. 시장에서의 고객 수요 변화에는 어떤 것들이 있는가?
- Q.8. 이 시장의 새로운 발전과 그 발전을 주도하고 있는 기업은?
- Q.9. 이 시장의 주요 기업은? 주요 기업들은 사업 성장을 위해 어떤 전략적 노력을 기울이고 있는가?
- Q.10. 이 시장의 경쟁 제품에는 어떤 것들이 있으며, 소재 및 제품 대체에 따른 시장 점유율 하락의 위협은 어느 정도인가?
- Q.11. 지난 5년간 어떤 M&A가 이루어졌고, 업계에 어떤 영향을 미쳤는가?
목차
제1장 주요 요약
제2장 세계의 백혈병 치료제 시장 : 시장 역학
- 서론, 배경, 분류
- 공급망
- 업계 촉진요인과 과제
제3장 시장 동향과 예측 분석 : 2018-2030년
- 거시경제 동향(2018-2023년)과 예측(2024-2030년)
- 세계의 백혈병 치료제 시장 동향(2018-2023년)과 예측(2024-2030년)
- 세계의 백혈병 치료제 시장 : 유형별
- 급성 림프성 백혈병
- 급성 골수성 백혈병
- 만성 림프성 백혈병
- 만성 골수성 백혈병
- 기타
- 세계의 백혈병 치료제 시장 : 약제별
- 화학요법
- 표적치료 및 면역치료
- 세계의 백혈병 치료제 시장 : 유통 채널별
- 병원 약국
- 드럭스토어 및 소매 약국
- 온라인 공급업체
제4장 시장 동향과 예측 분석 : 지역별(2018-2030년)
- 세계의 백혈병 치료제 시장 : 지역별
- 북미의 백혈병 치료제 시장
- 유럽의 백혈병 치료제 시장
- 아시아태평양의 백혈병 치료제 시장
- 기타 지역의 백혈병 치료제 시장
제5장 경쟁 분석
- 제품 포트폴리오 분석
- 운영상 통합
- Porter의 Five Forces 분석
제6장 성장 기회와 전략적 분석
- 성장 기회 분석
- 유형별 세계의 백혈병 치료제 시장 성장 기회
- 약제별 세계의 백혈병 치료제 시장 성장 기회
- 유통 채널별 세계의 백혈병 치료제 시장 성장 기회
- 지역별 세계의 백혈병 치료제 시장 성장 기회
- 세계 백혈병 치료제 시장의 새로운 동향
- 전략적 분석
- 신제품 개발
- 세계의 백혈병 치료제 시장 능력 확대
- 세계의 백혈병 치료제 시장의 인수합병(M&A) 및 합작투자(JV)
- 인증 및 라이선싱
제7장 유력 기업의 기업 개요
- Bristol-Myers Squibb
- Takeda Pharmaceutical
- Lupin
- Gilead Sciences
- Novartis
- Amgen
- Teva Pharmaceutical Industries
- Abbvie
- Pfizer
- Sanofi
Leukemia Therapeutics Trends and Forecast
The future of the global leukemia therapeutics market looks promising with opportunities in the hospital pharmacies, drug store and retail pharmacies, and online provider markets. The global leukemia therapeutics market is expected to reach an estimated $21.46 billion by 2030 with a CAGR of 8.4% from 2024 to 2030. The major drivers for this market are growing incidence of leukemia, increasing need for more effective treatment for lukemia and rising R&D spending in the healthcare industry.
A more than 150-page report is developed to help in your business decisions.
Leukemia Therapeutics by Segment
The study includes a forecast for the global leukemia therapeutics by type, drug, distribution channel, and region.
Leukemia Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:
- Acute Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- Others
Leukemia Therapeutics Market by Drug [Shipment Analysis by Value from 2018 to 2030]:
- Chemotherapy
- Targeted Therapy and Immunotherapy
Leukemia Therapeutics Market by Distribution channel [Shipment Analysis by Value from 2018 to 2030]:
- Hospital Pharmacies
- Drug Store and Retail Pharmacies
- Online Providers
Leukemia Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of Leukemia Therapeutics Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies leukemia therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the leukemia therapeutics companies profiled in this report include-
- Bristol-Myers Squibb
- Takeda Pharmaceutical
- Lupin
- Gilead Sciences
- Novartis
- Amgen
- Teva Pharmaceutical Industries
- Abbvie
- Pfizer
- Sanofi
Leukemia Therapeutics Market Insights
Lucintel forecasts that chronic lymphocytic leukemia will remain the largest segment over the forecast period due to increase in product approvals for chronic lymphocytic leukemia and presence of leukemia therapeutics for chronic lymphocytic leukemia.
Within this market, hospital pharmacies will remain the largest segment due to growing public awareness regarding leukemia and its treatment options along with increasing number of people seeking treatment in hospitals.
North America is expected to witness highest growth over the forecast period due to growing research in the field of regenerative medicine for the treatment of leukemia and rising awareness on personalized medicine in the region.
Features of the Global Leukemia Therapeutics Market
Market Size Estimates: Leukemia therapeutics market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Leukemia therapeutics market size by type, drug, distribution channel, and region in terms of value ($B).
Regional Analysis: Leukemia therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, drugs, distribution channels, and regions for the leukemia therapeutics market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the leukemia therapeutics market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q.1 What is the leukemia therapeutics market size?
Answer: The global leukemia therapeutics market is expected to reach an estimated $21.46 billion by 2030.
Q.2 What is the growth forecast for leukemia therapeutics market?
Answer: The global leukemia therapeutics market is expected to grow with a CAGR of 8.4% from 2024 to 2030.
Q.3 What are the major drivers influencing the growth of the leukemia therapeutics market?
Answer: The major drivers for this market are growing incidence of leukemia, increasing need for more effective treatment for lukemia and rising R&D spending in the healthcare industry.
Q4. What are the major segments for leukemia therapeutics market?
Answer: The future of the leukemia therapeutics market looks promising with opportunities in the hospital pharmacies, drug store and retail pharmacies, and online provider markets.
Q5. Who are the key leukemia therapeutics market companies?
Answer: Some of the key leukemia therapeutics companies are as follows:
- Bristol-Myers Squibb
- Takeda Pharmaceutical
- Lupin
- Gilead Sciences
- Novartis
- Amgen
- Teva Pharmaceutical Industries
- Abbvie
- Pfizer
- Sanofi
Q6. Which leukemia therapeutics market segment will be the largest in future?
Answer: Lucintel forecasts that chronic lymphocytic leukemia will remain the largest segment over the forecast period due to increase in product approvals for chronic lymphocytic leukemia and presence of leukemia therapeutics for chronic lymphocytic leukemia.
Q7. In leukemia therapeutics market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness highest growth over the forecast period due to growing research in the field of regenerative medicine for the treatment of leukemia and rising awareness on personalized medicine in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
- Q.1. What are some of the most promising, high-growth opportunities for the leukemia therapeutics market by type (acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia,chronic myeloid leukemia, and others), drug (chemotherapy, and targeted therapy & immunotherapy), distribution channel (hospital pharmacies, drug store and retail pharmacies, and online providers), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
- Q.2. Which segments will grow at a faster pace and why?
- Q.3. Which region will grow at a faster pace and why?
- Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
- Q.5. What are the business risks and competitive threats in this market?
- Q.6. What are the emerging trends in this market and the reasons behind them?
- Q.7. What are some of the changing demands of customers in the market?
- Q.8. What are the new developments in the market? Which companies are leading these developments?
- Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
- Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
- Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Table of Contents
1. Executive Summary
2. Global Leukemia Therapeutics Market : Market Dynamics
- 2.1: Introduction, Background, and Classifications
- 2.2: Supply Chain
- 2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
- 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
- 3.2. Global Leukemia Therapeutics Market Trends (2018-2023) and Forecast (2024-2030)
- 3.3: Global Leukemia Therapeutics Market by Type
- 3.3.1: Acute Lymphocytic Leukemia
- 3.3.2: Acute Myeloid Leukemia
- 3.3.3: Chronic Lymphocytic Leukemia
- 3.3.4: Chronic Myeloid Leukemia
- 3.3.5: Others
- 3.4: Global Leukemia Therapeutics Market by Drug
- 3.4.1: Chemotherapy
- 3.4.2: Targeted Therapy and Immunotherapy
- 3.5: Global Leukemia Therapeutics Market by Distribution channel
- 3.5.1: Hospital Pharmacies
- 3.5.2: Drug Store and Retail Pharmacies
- 3.5.3: Online Providers
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
- 4.1: Global Leukemia Therapeutics Market by Region
- 4.2: North American Leukemia Therapeutics Market
- 4.2.2: North American Leukemia Therapeutics Market by Distribution channel: Hospital Pharmacies, Drug Store and Retail Pharmacies, and Online Providers
- 4.3: European Leukemia Therapeutics Market
- 4.3.1: European Leukemia Therapeutics Market by Type: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, and Others
- 4.3.2: European Leukemia Therapeutics Market by Distribution channel: Hospital Pharmacies, Drug Store and Retail Pharmacies, and Online Providers
- 4.4: APAC Leukemia Therapeutics Market
- 4.4.1: APAC Leukemia Therapeutics Market by Type: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, and Others
- 4.4.2: APAC Leukemia Therapeutics Market by Distribution channel: Hospital Pharmacies, Drug Store and Retail Pharmacies, and Online Providers
- 4.5: ROW Leukemia Therapeutics Market
- 4.5.1: ROW Leukemia Therapeutics Market by Type: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, and Others
- 4.5.2: ROW Leukemia Therapeutics Market by Distribution channel: Hospital Pharmacies, Drug Store and Retail Pharmacies, and Online Providers
5. Competitor Analysis
- 5.1: Product Portfolio Analysis
- 5.2: Operational Integration
- 5.3: Porter's Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
- 6.1: Growth Opportunity Analysis
- 6.1.1: Growth Opportunities for the Global Leukemia Therapeutics Market by Type
- 6.1.2: Growth Opportunities for the Global Leukemia Therapeutics Market by Drug
- 6.1.3: Growth Opportunities for the Global Leukemia Therapeutics Market by Distribution channel
- 6.1.4: Growth Opportunities for the Global Leukemia Therapeutics Market by Region
- 6.2: Emerging Trends in the Global Leukemia Therapeutics Market
- 6.3: Strategic Analysis
- 6.3.1: New Product Development
- 6.3.2: Capacity Expansion of the Global Leukemia Therapeutics Market
- 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Leukemia Therapeutics Market
- 6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
- 7.1: Bristol-Myers Squibb
- 7.2: Takeda Pharmaceutical
- 7.3: Lupin
- 7.4: Gilead Sciences
- 7.5: Novartis
- 7.6: Amgen
- 7.7: Teva Pharmaceutical Industries
- 7.8: Abbvie
- 7.9: Pfizer
- 7.10: Sanofi
